Notice of cancelled AGM

RNS Number : 8579F
Novacyt S.A.
13 July 2023

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

Notice of cancelled AGM

New AGM to be held by the end of October 2023

Paris, France and Eastleigh, UK - 13 July 2023 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company's Annual General Meeting (AGM), due to take place on 10 August 2023 has been cancelled and will be held by the end of October.

In the absence of a quorum at the AGM convened for 15 June 2023, a second meeting was planned for 10 August 2023. Following the recent announcement concerning the recommended cash offer for Yourgene Health plc and following consent from the French court to delay approval of the FY2022 Accounts until 31 October 2023, the Company now intends to hold an AGM later in 2023 enabling as many shareholders as possible to attend, which is not possible during the summer months.

Forms of Proxy already received will unfortunately be void and full details of the new AGM and dates concerning voting will follow in due course.

Contacts

Novacyt SA James Wakefield, Non-Executive Chairman James McCarthy, Acting Chief Executive Officer	+44 (0)23 8074 8830
SP Angel Corporate Finance LLP (Nominated Adviser and Broker) Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking)	+44 (0)20 3470 0470
Numis (Joint Broker) Freddie Barnfield / Duncan Monteith / Jack McLaren	+44 (0)20 7260 1000

Allegra Finance (French Listing Sponsor)
Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10 r.durgetto@allegrafinance.com / y.petit@allegrafinance.com

Walbrook PR (Financial PR & IR)
Stephanie Cuthbert / Anna Dunphy / Phillip Marriage

+44 (0)20 7933 8780
novacyt@walbrookpr.com

About Novacyt Group

Novacyt is an international diagnostics business delivering a broad portfolio of in vitro and molecular diagnostic tests for a wide range of infectious diseases, enabling faster, more accurate, accessible testing to improve healthcare outcomes. The Company provides customers with a seamless sample-to-result workflow using its integrated and scalable instrumentation/solutions. The Company specialises in the design, manufacture, and supply of real-time PCR kits, reagents and a full range of laboratory and qPCR instrumentation for molecular biology research and clinical use. Novacyt offers one of the world's most varied and comprehensive range of qPCR assays, covering human, veterinary, biodefence, environmental, agriculture and food testing.

Novacyt is headquartered in Vélizy in France with offices in Stokesley and Eastleigh, UK, and is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCKLLFFXDLXBBZ